Genpharm at the 3rd Annual World Orphan Drug Congress

Geneva (Switzerland)– November 30, 2012 – The biggest annual European gathering assembling companies specialized in the development and commercialization of Orphan Drugs has just concluded its two days 2012 edition in Geneva.

The meeting brought together more than 250 experts working in the rare disease community, to share insights on the latest developments and discuss solutions to the most poignant challenges facing the industry.

The forum covered in depth through keynote speakers, panel discussions and debates, issues ranging from clinical development and R&D, market access, pricing and reimbursement, as well as partnerships and corporate development strategies. It also provided a platform for networking and future collaborations.

Genpharm Services introduced the untapped potential and the opportunities in the Middle East and North Africa Region (MENA) for companies operating in the space of rare disease and orphan drugs. We shared our regional insight and expertise by offering our holistic Market Access strategy ranging from registration to market penetration to patient follow up and registries.

About Genpharm Services

Genpharm Services is a pharmaceutical marketing company, based in the Dubai Biotechnology and Research Park, UAE. Through evidence based medicine, Genpharm provides healthcare organizations with innovative therapeutic solutions in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions in the Middle East and North Africa Region.

For more information, please visit 

For more information

Genpharm Services:

Karim Smaira Chief Executive Officer +971 4 422 70 10     Ashwathy Anil BusinessDevelopment +971 4 422 70 10 

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of Genpharm Services and the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond “Genpharm Services’’ control. Therefore, actual results, the financial condition, performance or achievements of Genpharm Services, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Genpharm Services disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in Genpharm Services expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by the UAE law.